- Home
- PSTL vs ZNTL Comparison
PSTL vs ZNTL Comparison
Compare PSTL & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSTL
- ZNTL
- Stock Information
- Founded
- PSTL 2018
- ZNTL 2014
- Country
- PSTL United States
- ZNTL United States
- Employees
- PSTL N/A
- ZNTL N/A
- Industry
- PSTL Real Estate Investment Trusts
- ZNTL Biotechnology: Pharmaceutical Preparations
- Sector
- PSTL Real Estate
- ZNTL Health Care
- Exchange
- PSTL Nasdaq
- ZNTL Nasdaq
- Market Cap
- PSTL 320.0M
- ZNTL 238.2M
- IPO Year
- PSTL 2019
- ZNTL 2020
- Fundamental
- Price
- PSTL $14.62
- ZNTL $3.12
- Analyst Decision
- PSTL Buy
- ZNTL Buy
- Analyst Count
- PSTL 2
- ZNTL 7
- Target Price
- PSTL $15.75
- ZNTL $10.86
- AVG Volume (30 Days)
- PSTL 67.9K
- ZNTL 1.2M
- Earning Date
- PSTL 11-01-2024
- ZNTL 11-04-2024
- Dividend Yield
- PSTL 6.58%
- ZNTL N/A
- EPS Growth
- PSTL N/A
- ZNTL N/A
- EPS
- PSTL 0.09
- ZNTL N/A
- Revenue
- PSTL $68,445,000.00
- ZNTL $40,560,000.00
- Revenue This Year
- PSTL N/A
- ZNTL N/A
- Revenue Next Year
- PSTL $12.21
- ZNTL N/A
- P/E Ratio
- PSTL $167.49
- ZNTL N/A
- Revenue Growth
- PSTL 15.46
- ZNTL N/A
- 52 Week Low
- PSTL $13.00
- ZNTL $2.83
- 52 Week High
- PSTL $15.15
- ZNTL $18.24
- Technical
- Relative Strength Index (RSI)
- PSTL 55.79
- ZNTL 44.34
- Support Level
- PSTL $14.46
- ZNTL $2.92
- Resistance Level
- PSTL $14.73
- ZNTL $3.23
- Average True Range (ATR)
- PSTL 0.19
- ZNTL 0.17
- MACD
- PSTL 0.04
- ZNTL 0.00
- Stochastic Oscillator
- PSTL 84.87
- ZNTL 38.33
About PSTL Postal Realty Trust Inc.
Postal Realty Trust Inc is an internally managed real estate corporation that owns and manages properties leased to the United States Postal Service, or the USPS. Its objective is to create stockholder value by generating risk-adjusted returns through expanding its portfolio of owned and managed postal properties leased to the USPS. The majority of the revenue is generated from the rental income received.
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.